|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 38/17 | (2006.01) |
| A61K 38/1709 | (2013.01) | ||
| A61P 27/02 | (2006.01) | ||
| A61P 27/02 | (2018.01) |
| (11) | Number of the document | 4429693 |
| (13) | Kind of document | T |
| (96) | European patent application number | 23730718.6 |
| Date of filing the European patent application | 2023-05-18 | |
| (97) | Date of publication of the European application | 2024-09-18 |
| (45) | Date of publication and mention of the grant of the patent | 2025-02-26 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/EP2023/063441 |
| Date | 2023-05-18 |
| (87) | Number | WO 2023/227468 |
| Date | 2023-11-30 |
| (30) | Number | Date | Country code |
| 202207263 | 2022-05-18 | GB |
| (72) |
FROSTEGÅRD, Anna , SE
HAEGERSTRAND, Anders , SE
|
| (73) |
Annexin Pharmaceuticals AB ,
Kammakargatan 48, 111 60 Stockholm,
SE
|
| (54) | MONOMERIC ANNEXIN A5 FOR USE IN THE TREATMENT OF MACULAR OEDEMA OR RETINAL VEIN OCCLUSION |
| MONOMERIC ANNEXIN A5 FOR USE IN THE TREATMENT OF MACULAR OEDEMA OR RETINAL VEIN OCCLUSION |